Evidence map›Paper›PMID 41085811›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2025

Lipid-Metabolically Active TREM2

Jinxin Li, Xiaotong Yu, Decao Yang, Shaomeng Chen, Jiaxing Xu, Xiaojuan Ma, Chen Huang, Baohui Xu, Lixiang Xue, Yan Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Decoding the Prognosis-Related S100A9OncoTargets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jinxin Li *Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Xiaotong Yu *Institute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Decao YangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Shaomeng ChenInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Jiaxing XuInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Xiaojuan MaInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Chen HuangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China.
Baohui XuDivision of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA, USA.
Lixiang XueInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. lixiangxue@hsc.pku.edu.cn.
Yan WangInstitute of Medical Innovation and Research, Peking University Third Hospital, Beijing, China. yanwang2019@bjmu.edu.cn.

Funding

National Natural Science Foundation of China 82471329
6 · The paper itself

Abstract

Gliomas are the most common primary brain tumors and characterized by poor prognosis and heavy infiltration of tumor-associated macrophages. Triggering receptor expressed on myeloid cells-2 (TREM2), known to modulate macrophage function, has shown conflicting roles in glioma pathology. In this study, we comprehensively investigated the expression, function, and clinical relevance of TREM2 in gliomas using public datasets, single-cell RNA sequencing (scRNA-seq) analysis, and multiplex immunofluorescence. scRNA-seq identified a distinct subset of microglia-derived macrophages with high TREM2 expression that exhibit a dual phenotype of immunosuppression and enhanced lipid metabolism. These cells show enrichment of genes involved in fatty acid metabolism and lipoprotein clearance, including significant upregulation of apolipoprotein E (APOE), a known TREM2 ligand. Clinically, high TREM2 expression in microglia-derived macrophages correlates with increased tumor grade, recurrence, and shorter overall and disease-free survival. In contrast, APOE expression was correlated with better survival in public datasets, though not significantly in our patient cohort. Our findings suggest that TREM2

Indexed as

Brain NeoplasmsGliomaImmunotherapyLipid MetabolismMacrophagesMembrane GlycoproteinsMicrogliaReceptors, ImmunologicFemaleHumansMaleMiddle AgedPrognosisTumor-Associated MacrophagesMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanAPOEGliomaMacrophageMicrogliaTREM2

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.